Elevated e-cadherin and α/β-catenin expression after androgen deprivation therapy in prostate adenocarcinoma

Pathology Research and Practice

Volumn 199, Issue 10, 2003, Pages 659-665

  Patriarca, Carlo ^a   Petrella, D ^a   Campo, B ^a   Colombo, P ^b   Giunta, P ^a   Parente, M ^a   Zucchini, N ^a   Mazzucchelli, R ^c   Montironi, R ^c  

^a Ospedale Predabissi   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alpha beta catenins; Antiandrogen; E cadherin; Prostate adenocarcinoma

Indexed keywords

ALPHA CATENIN; ANTIANDROGEN; BETA CATENIN; BICALUTAMIDE; CELL ADHESION MOLECULE; UVOMORULIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; PROTEIN EXPRESSION; SCORING SYSTEM;

EID: 0345169908     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1078/0344-0338-00477     Document Type: Article

References (21)

1. Armas OA, Aprikian AG, Melamed J Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE (1994) Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18: 979-991
2. Bazinet M, Zheng W, Begin LR, Aprikian AG, Karakiewicz PI, Elhilali MM (1997) Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49: 721-725
3. Bono A, Pagano F, Montironi R et al. (2001) Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT Study. Urology 57: 117-121
4. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI (1999) E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53: 707-713
5. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, Eeles, RA, Kirby RS (2000) Molecular markers for predicting prostate cancer stage and survival. Br J Urol Int 86: 869-878
6. Epstein JI (1995) Prostate biopsy interpretation. 2nd edn. Philadelphia: Lippincott-Raven Publishers. 65-85
7. Fiocca R, Luinetti O, Villani L, Mastracci L, Quilici P, Grillo F, Ranzani GN (2001) Molecular mechanisms involved in pathogenesis of gastric carcinoma: interactions between genetic alterations, cellular phenotype and cancer histotype. Hepatogastroenterology 48: 1523-1530
8. Lehr HA, Folpe A, Yaziji H, Kommoss F, Gown AM (2000) Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 114: 190-196
9. Montironi R, Schulman CC (1998) Pathologic changes in prostate lesions after androgen manipulation. J Clin Pathol 51: 5-12
10. Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y, Okajima E, Konishi N, Hiasa Y (1999) E-cadherin and alpha-, beta and gamma-catenin expression in prostate cancer: correlation with tumor invasion. Br J Cancer 79: 1879-1883
11. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ (1997) Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33: 263-271
12. Reuter VE (1997) Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49: 16-22
13. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G (2003) A 10 year clinical experience with intermittent hormonal therapy in prostate cancer. Eur Urol 43 (3): 233-239
14. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HAG, Nazeer T, Jennings TA, Ingle R, Nack Kim D (1994) E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 7: 835-840
15. Ross JS, Sheehan CE, Dolen EM, Kallakury BVS (2002) Morphologic and molecular prognostic markers in prostate cancer. Adv in Anat Pathol 9: 115-128
16. Shi SR, Key ME, Kalza KL (1991) Antigen retrieval in formalin fixed, paraffin embedded tissues. An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748
17. Small EJ, Vogelzang NJ (1997) Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15: 382-388
18. Tetu B, Srigley JR, Boivin JC, Dupont A, Monfette G, Pinault S, Labrie F (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 15: 111-120
19. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ, Schalken JA (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933
20. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, Debruyne FMJ, Isaacs WB (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52: 5104-5109
21. Van Aken E, De Wever O, Correia da Rocha AS, Mereel M (2001) Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 439: 725-751